News

December 1, 2017December 1, 2017

European Commission Approves Tesaro’s Zejula as Maintenance Therapy for Ovarian Cancer

News

The European Commission has approved Tesaro‘s Zejula (niraparib) as a maintenance treatment for ovarian cancer, with or without BCRA mutations, in women who have shown a complete or partial response ... Read more

November 29, 2017

SOTIO Enrolls First Patient in Another Phase 2 Trial of Its Ovarian Cancer Immunotherapy

News

SOTIO has enrolled its first ovarian cancer patient in a Phase 2 clinical trial evaluating its immunotherapy DCVAC/OvCa. The SOV06 trial will look at the therapy’s effectiveness as an add-on to ... Read more

November 27, 2017

First Patients Enroll in Phase 2 Trial of Acelarin as Treatment for Chemo-resistant Ovarian Cancer

News

NuCana has started a Phase 2 clinical trial of its ovarian cancer therapy Acelarin (NUC-1031) by enrolling the first patients in the United States and Britain. It will continue to recruit 64 participants who ... Read more

November 20, 2017November 20, 2017

New Drug Discovery Program Identifies Potential Treatments for Ovarian Cancer, Other Diseases

News

Researchers have developed a new computer program, known as DrugPredict, to find new therapeutics for unmet diseases, like ovarian cancer, among medications the U.S. Food and Drug Administration (FDA) has already ... Read more

November 17, 2017November 17, 2017

ARRY-382-Keytruda Combo Shows Positive Results in Ovarian, Other Solid Cancers

News

The combination of Array BioPharma‘s immunotherapy ARRY-382 and Keytruda (pembrolizumab) has a manageable safety profile and has shown preliminary signs of effectiveness in pancreatic and ovarian cancer patients, a new Phase 1b ... Read more

November 15, 2017November 15, 2017

OncoQuest, Tesaro Team Up to Test Oregovomab-Zejula Combo

News

OncoQuest has entered into a collaborative agreement with Tesaro to conduct a proof-of-concept clinical trial evaluating the combination of oregovomab (MAb B43.13) with Zejula (niraparib) in recurrent ovarian cancer. Oregovomab is ... Read more

November 13, 2017November 13, 2017

PharmaMar Partners with Foundation for Women’s Cancer to Support D.C. National 5K Race

News

Spain’s PharmaMar partnered with the Foundation for Women’s Cancer (FWC) on Nov. 5 to support the 8th National Race to End Women’s Cancer in Washington, D.C. The race featured a 5k run and a ... Read more

November 8, 2017

Study Examines Chemotherapy Options for Partially Platinum-Sensitive OC Patients

News

Platinum-based chemotherapy (PBC) should be not be delayed in favor of non-platinum-based chemotherapy (NPBC) in patients with partially platinum-sensitive ovarian cancer, a new study shows. The study, “Randomized Controlled Trial ... Read more

November 6, 2017

Siamab’s Antibody-drug Conjugates for Ovarian Cancer Seen to Succeed in Animal Models

News

Siamab Therapeutics’ preclinical work with anti-STn antibody-drug conjugates is moving forward, and in animal models — including primates — it showed the conjugates could safely and effectively treat ovarian cancer ... Read more

November 3, 2017

FDA OKs Mersana’s XMT-1536 for Clinical Investigation in Ovarian, Other Solid Tumors

News

Mersana Therapeutics is advancing its antibody-drug conjugate XMT-1536 into clinical development for ovarian and other tumor types, after the U.S. Food and Drug Administration cleared the company’s investigational new drug (IND) ... Read more